EGFR and ovarian carcinoma: In combination treatments BEZ235 has been shown to overcome resistance to epidermal growth factor receptor (ErbB) inhibitors in breast cancer [32], to sensitize ovarian carcinoma cells to anti-apoptosis inhibitors [33], to enhance sensitivity to PARP inhibitors in breast cancer cells and to re-sensitize cells to cisplatin in bladder and ovarian cancer cell lines [29,31].